Oxybutynin Chloride Tablet
Product Images NDC 82868-047

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 82868-047). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (82868 047 30 Rev A 02 24)

Label (82868 047 30 Rev A 02 24)
Oxybutynin Chloride Tablets, USP 5 mg, oral dosage form in a package containing 30 tablets. The label includes storage instructions and manufacturer information for Northwind Health Company, LLC. It displays the product NDC 82868-047-30 and specifies Rx only.*
FDA Label Image

Structural Formula (Figure 1 Structure)

Structural Formula (Figure 1 Structure)
Chemical structure of Oxybutynin Chloride, illustrating its molecular configuration with specific functional groups and atoms labeled, including aromatic rings, ester linkages, and side chains.*
FDA Label Image

Table 1 (Figure 2 Table1)

Table 1 (Figure 2 Table1)
A data table presenting pharmacokinetic parameters of R-Oxybutynin and S-Oxybutynin, including maximum concentration (Cmax), time to maximum concentration (Tmax), and area under the concentration-time curve (AUC). Values are given with units and standard deviations.*
FDA Label Image

Figure 1 (Figure 3 Figure1)

Figure 1 (Figure 3 Figure1)
A pharmacokinetic line graph showing mean plasma R-oxybutynin concentration (ng/mL) over 24 hours after oral administration of Oxybutynin 5 mg taken three times daily (TID). The plot includes error bars indicating variability at each time point, with concentration peaks occurring at several intervals within the day.*
FDA Label Image

Table 2 (Figure 4 Table2)

Table 2 (Figure 4 Table2)
A data table presenting pharmacokinetic parameters including Cmax, Tmax, and AUC for four analytes: R-Oxybutynin, S-Oxybutynin, R-Desethyloxybutynin, and S-Desethyloxybutynin, with values given as means plus or minus standard deviations.*
FDA Label Image

Figure 2 (Figure 5 Figure2)

Figure 2 (Figure 5 Figure2)
A line graph depicting mean R-Oxybutynin plasma concentration (ng/mL) over time (hours). The y-axis shows concentration from 0 to 10 ng/mL with data points and error bars, while the x-axis shows time points from 0 to 12 hours, illustrating changes in plasma concentration across this timeframe.*
FDA Label Image

Table 3 (Figure 6 Table3)

Table 3 (Figure 6 Table3)
A data table listing adverse events associated with Oxybutynin Chloride (5-20 mg/day) in 199 subjects. It categorizes events by body system and provides percentages for occurrences such as urinary tract infection (6.5%), insomnia (5.5%), dizziness (16.6%), blurred vision (9.6%), dry mouth (71.4%), and urinary hesitation (8.5%).*
FDA Label Image
Kvk Logo (Figure 7 Company Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.